The document discusses treatment regimens for gastric cancer including preoperative and postoperative chemotherapy, preoperative chemoradiation, postoperative chemoradiation, and chemotherapy for metastatic or locally advanced cancer. It provides dosing details for various chemotherapy drugs and combinations such as DCF (docetaxel, cisplatin, 5-fluorouracil), ECF (epirubicin, cisplatin, 5-fluorouracil), and trastuzumab with capecitabine or 5-fluorouracil for HER2-positive cancers. The regimens may include both FDA-approved and unapproved uses and clinicians must choose treatments based on individual patients.